Source: BioSpace
Area: News
According to BioSpace, squalamine eye drops have been granted Fast Track designation by the US FDA for the potential treatment of the wet form of age-related macular degeneration (wet AMD).
Squalamine is s small molecule inhibitor of multiple growth factors implicated in angiogenesis, including Vascular Endothelial Growth Factor (VEGF) and Platelet Derived Growth Factor (PDGF); the latter has recently been identified as an additional key target for the treatment of wet AMD. An intravenous formulation of squalamine has been found in Phase I and II (Read more...)
Uncategorized